Childhood kidney neoplasm
disease diseaseOn this page
Also known as childhood kidney tumorchildhood kidney tumourchildhood renal neoplasmchildhood renal tumorchildhood renal tumourkidney neoplasmkidney neoplasm of childhoodpaediatric kidney neoplasmpaediatric kidney tumourpaediatric renal neoplasmpaediatric renal tumourpediatric kidney neoplasmpediatric kidney tumorpediatric renal neoplasmpediatric renal tumor
Summary
Childhood kidney neoplasm (MONDO:0002730) is a cancer and 111 clinical trials. Top therapeutic interventions include sunitinib, axitinib, and indocyanine green acid form. A subtype of childhood neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 111
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | childhood kidney neoplasm |
| Mondo ID | MONDO:0002730 |
| DOID | DOID:3675 |
| NCIT | C6563 |
| UMLS | C1333003 |
| MedGen | 232356 |
| Is cancer (heuristic) | yes |
Also known as: childhood kidney neoplasm · childhood kidney tumor · childhood kidney tumour · childhood renal neoplasm · childhood renal tumor · childhood renal tumour · kidney neoplasm · kidney neoplasm of childhood · paediatric kidney neoplasm · paediatric kidney tumour · paediatric renal neoplasm · paediatric renal tumour · pediatric kidney neoplasm · pediatric kidney tumor · pediatric renal neoplasm · pediatric renal tumor
Data availability: 2 cell lines.
Disease family
This is a subtype of childhood neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › childhood neoplasm › childhood kidney neoplasm
Related subtypes (13): childhood astrocytic tumor, childhood spinal cord tumor, childhood infratentorial neoplasm, pediatric meningioma, childhood mediastinal neurogenic neoplasm, childhood ependymoma, childhood germ cell tumor, childhood optic nerve glioma, childhood malignant neoplasm, childhood carcinoid tumor, childhood choroid plexus neoplasm, childhood testicular neoplasm, childhood adrenal gland pheochromocytoma
Subtypes (3): childhood multilocular cystic kidney neoplasm, childhood kidney angiomyolipoma, childhood malignant kidney neoplasm
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 111.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 59 |
| PHASE2 | 22 |
| PHASE1 | 13 |
| PHASE3 | 7 |
| PHASE4 | 6 |
| PHASE1/PHASE2 | 3 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06903312 | PHASE4 | RECRUITING | Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations. |
| NCT01413607 | PHASE4 | TERMINATED | The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy |
| NCT03444766 | PHASE4 | COMPLETED | Study of Nivolumab for Advanced Cancers in India |
| NCT04513522 | PHASE4 | COMPLETED | A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India |
| NCT04854018 | PHASE4 | COMPLETED | Indo-cyanine Green (ICG) in Paediatric Oncology MIS |
| NCT05068180 | PHASE4 | UNKNOWN | Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients |
| NCT03091192 | PHASE3 | ACTIVE_NOT_RECRUITING | Savolitinib vs. Sunitinib in MET-driven PRCC. |
| NCT03669783 | PHASE3 | RECRUITING | Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm) |
| NCT06467097 | PHASE3 | RECRUITING | Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma |
| NCT00065468 | PHASE3 | COMPLETED | Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma |
| NCT00221728 | PHASE2/PHASE3 | TERMINATED | Comparison Between Surgery and Radiofrequency for Treatment of Renal Tumors |
| NCT00375674 | PHASE3 | COMPLETED | A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer |
| NCT00678392 | PHASE3 | COMPLETED | Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer |
| NCT00920816 | PHASE3 | COMPLETED | Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer |
| NCT04258462 | PHASE2 | ACTIVE_NOT_RECRUITING | Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors |
| NCT05944237 | PHASE1/PHASE2 | RECRUITING | HTL0039732 in Participants With Advanced Solid Tumours |
| NCT06680089 | PHASE2 | RECRUITING | CD70-targeted immunoPET Imaging of Kidney Cancer |
| NCT07225114 | PHASE2 | RECRUITING | Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging |
| NCT07397611 | PHASE2 | RECRUITING | Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC |
| NCT00035243 | PHASE2 | COMPLETED | EPO906 Therapy in Patients With Advanced Kidney Cancer |
| NCT00054886 | PHASE2 | COMPLETED | Study of the Safety and Efficacy of SU-011,248 in Adult Patients With Advanced Kidney Cancer |
| NCT00059735 | PHASE2 | COMPLETED | A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma |
| NCT00065572 | PHASE2 | SUSPENDED | Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly Diagnosed Metastatic Renal Cell Carcinoma (Stage IV) |
| NCT00076011 | PHASE2 | COMPLETED | Anti-angiogenesis Agent AG-013736 in Patients With Metastatic Renal Cell Carcinoma |
| NCT00101608 | PHASE2 | COMPLETED | Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium |
| NCT00123773 | PHASE2 | COMPLETED | Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence |
| NCT00134186 | PHASE2 | COMPLETED | Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer |
| NCT00226980 | PHASE2 | COMPLETED | A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma |
| NCT00282048 | PHASE2 | COMPLETED | Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer |
| NCT00651482 | PHASE2 | TERMINATED | Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus) |
| NCT01154816 | PHASE2 | COMPLETED | Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia |
| NCT01633255 | PHASE1/PHASE2 | WITHDRAWN | [18]F-Fluciclatide for Kidney Cancer Imaging Studies and Treatment |
| NCT01688999 | PHASE2 | COMPLETED | Cabozantinib for Advanced Urothelial Cancer |
| NCT01712685 | PHASE2 | TERMINATED | Imaging Studies of Kidney Cancer Using 18F-VM4-037 |
| NCT01961583 | PHASE2 | TERMINATED | [18F]Fluciclatide PET Imaging of Pazopanib Response |
| NCT02689167 | PHASE2 | UNKNOWN | Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma |
| NCT04644432 | PHASE2 | UNKNOWN | Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma |
| NCT05119335 | PHASE1/PHASE2 | TERMINATED | A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma |
| NCT05935748 | PHASE2 | TERMINATED | Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) |
| NCT00001302 | PHASE1 | COMPLETED | A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833 |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| SUNITINIB | 4 | 4 |
| AXITINIB | 4 | 3 |
| INDOCYANINE GREEN ACID FORM | 4 | 2 |
| NIVOLUMAB | 4 | 2 |
| SORAFENIB | 4 | 2 |
| ALPELISIB | 4 | 1 |
| CABOZANTINIB | 4 | 1 |
| DACTINOMYCIN | 4 | 1 |
| FLUDARABINE PHOSPHATE | 4 | 1 |
| IPILIMUMAB | 4 | 1 |
| MUROMONAB-CD3 | 4 | 1 |
| TECHNETIUM TC 99M SESTAMIBI | 4 | 1 |
| TEMSIROLIMUS | 4 | 1 |
| VINBLASTINE | 4 | 1 |
| VINFLUNINE | 4 | 1 |
| VALSPODAR | 3 | 2 |
| ALISERTIB | 3 | 1 |
| FLUORIDE ION F-18 | 3 | 1 |
| INTERFERON ALFA | 3 | 1 |
| MOTEXAFIN GADOLINIUM | 3 | 1 |
| PATUPILONE | 3 | 1 |
| SASANLIMAB | 3 | 1 |
| SAVOLITINIB | 3 | 1 |
| ZIMBERELIMAB | 3 | 1 |
| CASDATIFAN | 2 | 1 |
| INDISULAM | 2 | 1 |
| ZD-6126 | 2 | 1 |
| CDX-014 | 1 | 1 |
| CHEMBL3939307 | 0 | 2 |
| CHEMBL275117 | 0 | 1 |
Related Atlas pages
- Drugs: Sunitinib, Axitinib, Indocyanine Green Acid Form, Nivolumab, Sorafenib, Alpelisib, Cabozantinib, Dactinomycin, Fludarabine Phosphate, Ipilimumab, MUROMONAB-CD3, TECHNETIUM TC 99M SESTAMIBI, Temsirolimus, Vinblastine, Vinflunine, Valspodar, Alisertib, FLUORIDE ION F-18, Interferon Alfa, Motexafin Gadolinium, Patupilone, Sasanlimab, Savolitinib, Zimberelimab